Provided by Tiger Trade Technology Pte. Ltd.

Minerva Neurosciences

4.68
+0.620015.27%
Post-market: 4.680.00000.00%19:31 EST
Volume:191.08K
Turnover:889.62K
Market Cap:202.52M
PE:-2.53
High:4.91
Open:4.12
Low:4.12
Close:4.06
52wk High:12.46
52wk Low:1.15
Shares:43.27M
Float Shares:5.44M
Volume Ratio:3.27
T/O Rate:3.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8533
EPS(LYR):0.1901
ROE:-675.09%
ROA:-25.82%
PB:-5.86
PE(LYR):24.62

Loading ...

Minerva Neurosciences Hosts Virtual KOL Event on Roluperidone for Negative Symptoms of Schizophrenia

Reuters
·
Jan 26

Minerva Neurosciences Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 23, 2025

Minerva Neurosciences Expands Board Amid Fundraising Effort

TIPRANKS
·
Nov 19, 2025

BRIEF-Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors

Reuters
·
Nov 19, 2025

Minerva Neurosciences Appoints Dr. Inderjit Kaul to Board of Directors

Reuters
·
Nov 19, 2025

Minerva Neurosciences Appoints DR. Inderjit Kaul to the Company’s Board of Directors

THOMSON REUTERS
·
Nov 19, 2025

Minerva Neurosciences Files Initial Beneficial Ownership Statement for Director Inderjit Kaul

Reuters
·
Nov 19, 2025

Minerva Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Nov 15, 2025

Minerva Neurosciences Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 11, 2025

Minerva Neurosciences (NERV) Gets a Hold from H.C. Wainwright

TIPRANKS
·
Nov 10, 2025

Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Nov 06, 2025

Minerva price target lowered to $4 from $5 at H.C. Wainwright

TIPRANKS
·
Nov 06, 2025

Minerva Neurosciences reports $2.7 mln Q3 net loss

Reuters
·
Nov 05, 2025

Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate

Benzinga
·
Nov 05, 2025

BRIEF-Minerva Neurosciences Q3 Net Income USD -2.744 Million

Reuters
·
Nov 05, 2025

Minerva Neurosciences Secures $80 Million Financing and Plans Phase 3 Roluperidone Trial

Reuters
·
Nov 05, 2025

Minerva Neurosciences Q3 Operating Expenses USD 2.844 Million

THOMSON REUTERS
·
Nov 05, 2025

Minerva Neurosciences Inc: on a Path Forward to Advancing Roluperidone for Treatment of Negative Symptoms of Schizophrenia

THOMSON REUTERS
·
Nov 05, 2025

Minerva Neurosciences: R&D,Admin Costs May Rise, but We’re Well Positioned to Fund Phase 3, Nda Resubmission and Launch Prep for Roluperidone in US

THOMSON REUTERS
·
Nov 05, 2025

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Dow Jones
·
Oct 21, 2025